Insmed (INSM) PT Raised to $208 at Stifel: Arikayce Peak Sales Revised Upwards
Tweet Send to a Friend
Stifel analyst Stephen Willey raised the price target on Insmed (NASDAQ: INSM) to $208.00 (from $205.00) while maintaining a Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
